Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:EQ NASDAQ:MDVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$0.80-4.0%$2.88$0.69▼$29.40$5.41M1.27748,170 shs1.55 million shsEQEquillium$0.42-1.4%$0.36$0.27▼$1.50$14.83M1.86470,170 shs284,730 shsMDVLMedAvail$3.31$1.31▼$20.89$2.91M0.76261,432 shs245,100 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%-60.48%-74.41%-81.39%-94.22%EQEquillium0.00%+18.60%+28.71%-12.15%-55.21%MDVLMedAvail0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriacell Therap1.4556 of 5 stars3.52.00.00.00.60.00.6EQEquillium2.2127 of 5 stars3.24.00.00.00.61.70.6MDVLMedAvailN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 3.00Buy$32.003,908.52% UpsideEQEquillium 2.33Hold$3.00622.72% UpsideMDVLMedAvail 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MDVL, BCTX, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/AEQEquillium$30.41M0.49N/AN/A$0.54 per share0.77MDVLMedAvail$43.33M0.00N/AN/A$13.01 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/AEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)MDVLMedAvail-$47.62M-$28.72N/AN/AN/A-192.97%-218.10%-103.45%N/ALatest MDVL, BCTX, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AMDVLMedAvailN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41EQEquilliumN/A2.702.70MDVLMedAvailN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%EQEquillium27.05%MDVLMedAvailN/AInsider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%EQEquillium31.60%MDVLMedAvail1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap86.78 million6.39 millionNo DataEQEquillium4035.72 million24.43 millionNot OptionableMDVLMedAvail2791.61 million1.59 millionNo DataMDVL, BCTX, and EQ HeadlinesRecent News About These CompaniesDelhi Bank Corp DWNXApril 18, 2024 | morningstar.comMUS Stocks Mixed; Trimble Issues Weak OutlookFebruary 12, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.33%February 12, 2024 | msn.comMedAvail Holdings Faces Nasdaq Delisting After BankruptcyFebruary 9, 2024 | msn.comWall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than ExpectedFebruary 8, 2024 | msn.comUS Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade DataFebruary 8, 2024 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.37%February 6, 2024 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.37%February 6, 2024 | msn.comMedAvail Holdings Files for Chapter 7 BankruptcyFebruary 3, 2024 | msn.comDow Falls 150 Points; US Economy Adds 353,000 Jobs In JanuaryFebruary 2, 2024 | msn.comMedavail Holdings Inc (MDVL)January 31, 2024 | investing.comMedAvail Announces Agreement with New Orleans-Based St. Thomas Community Health Centers for Deployment of Two M4 MedCentersNovember 28, 2023 | finance.yahoo.comMedAvail Holdings Inc Ordinary Shares MDVLNovember 18, 2023 | morningstar.comMMedAvail Holdings, Inc.: MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-QNovember 18, 2023 | finanznachrichten.deMedAvail receives non-compliance notice from NasdaqNovember 17, 2023 | msn.comMedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-QNovember 17, 2023 | benzinga.comMedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-QNovember 17, 2023 | finance.yahoo.comMedAvail Announces Agreement with ASP Cares for Deployment of Ten M4 MedCentersNovember 17, 2023 | finance.yahoo.comMDVL, BACK and FTEL are among mid-day moversNovember 10, 2023 | msn.comMedAvail to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 30, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDVL, BCTX, and EQ Company DescriptionsBriacell Therap NASDAQ:BCTX$0.80 -0.03 (-3.98%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.81 +0.02 (+1.97%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Equillium NASDAQ:EQ$0.42 -0.01 (-1.40%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.43 +0.01 (+3.35%) As of 07/18/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.MedAvail NASDAQ:MDVLMedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.